08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

Onexton Gel clindamycin phosphate/benzoyl peroxide regulatory update

FDA approved Onexton Gel clindamycin phosphate/benzoyl peroxide from Valeant to treat acne vulgaris in patients ages =12 years. Valeant said it plans to launch the fixed combination of 1.2% clindamycin phosphate and 3.75% benzoyl peroxide...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Lumara Health, AMAG Pharmaceuticals deal

AMAG will acquire Lumara's maternal health business in a cash and stock deal. Lumara (formerly KV Pharmaceutical Co. ) will receive $600 million in cash and 3.2 million AMAG shares worth about $74.4 million based...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Lumara Health, Perrigo deal

Perrigo will acquire Lumara's OTC women's healthcare business for $82 million in cash. Perrigo will gain Lumara's Clindesse clindamycin phosphate and Gynazole-1 butoconazole nitrate vaginal creams and Evamist estradiol transdermal spray. Perrigo said it plans...
02:30 , Sep 30, 2014 |  BC Extra  |  Company News

AMAG gains on M&A deal to add Makena

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) jumped $6.54 (28%) to $29.72 Monday on news it agreed to acquire the maternal health business of Lumara Health Inc. (Chesterfield, Mo.) -- once known as KV Pharmaceutical Co. -- for...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

Galderma, PreCision Dermatology sales and marketing update

PreCision's Onset Dermatologics LLC subsidiary acquired worldwide rights to acne drug Clindagel 1% clindamycin from Galderma's Galderma Laboratories L.P. unit for an undisclosed amount. The product is a topical formulation of clindamycin phosphate. Clindagel will...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Company News

Valeant sales and marketing update

Valeant's Coria Laboratories Ltd. unit launched Acanya clindamycin/benzoyl peroxide in the U.S. to treat acne vulgaris in patients 12 years and older. The price is not disclosed. The combination of clindamycin phosphate 1.2% and benzoyl...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

Acanya gel regulatory update

FDA approved an NDA from Dow for topical Acanya gel to treat acne vulgaris in patients 12 years and older. Acanya is a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% in a gel....
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

Ziana Gel regulatory update

FDA approved the companies' NDA for Ziana Gel to treat acne vulgaris in patients 12 years and older. The drug contains clindamycin phosphate 1.2% and tretinoin 0.025%. Dow Pharmaceutical Sciences , Petaluma, Calif.   Medicis...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Clinical News

Clindamax clindamycin phosphate regulatory update

FDA approved Clindamax 2% clindamycin phosphate vaginal cream for 3 or 7 day treatment of bacterial vaginosis (BV). PharmaDerm , Atlanta, Ga.   Product: Clindamax clindamycin phosphate   Business: Infectious  ...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Clinical News

Clindesse clindamycin phosphate regulatory update

FDA approved an NDA for Clindesse 2% single-dose vaginal cream therapy to treat bacterial vaginosis. KV Pharmaceutical Company (KVA), St. Louis, Mo.   Product: Clindesse clindamycin phosphate   Business: Infectious  ...